Article
Agriculture, Dairy & Animal Science
Jiakun Yan, Chong Pan, Yanli Liu, Xujie Liao, Jionghao Chen, Yufei Zhu, Xinhuo Huang, Xiaojun Yang, Zhouzheng Ren
Summary: The present study evaluated the effects of dietary supplemental vitamin D-3 on fibroblast growth factor 23 (FGF23) signals, phosphorus homeostasis, and metabolism in laying hens. The results showed that restriction of dietary vitamin D-3 reduced serum phosphorus levels in laying hens and suppressed the expression of FGF23 signaling-related genes.
Review
Endocrinology & Metabolism
Pan-Pan Hu, Jing-Fu Bao, Aiqing Li
Summary: The fibroblast growth factor-23-alpha-Klotho axis is closely related to chronic kidney disease and has multiple biological functions beyond bone-mineral metabolism. Dysregulation of this axis has been observed in acute kidney injury, but its exact role in the pathophysiology of acute kidney injury remains largely unknown. It may provide new therapeutic targets for treating acute kidney injury.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Article
Cell Biology
Baris Afsar, Mehmet Kanbay, Rengin Elsurer Afsar
Summary: Bone marrow hematopoiesis is regulated by various factors, including bone components, EPO, and FGF23. The interaction between these factors involves HIF pathway, direct stimulation of FGF23 synthesis, and cleavage of FGF23. Recent evidence suggests a complex relationship between FGF23, klotho, EPO, and HIF in hematopoiesis.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2022)
Article
Neurosciences
Stan R. Ursem, Charlene Diepenbroek, Vesna Bacic, Unga A. Unmehopa, Leslie Eggels, Clarissa M. Maya-Monteiro, Annemieke C. Heijboer, Susanne E. la Fleur
Summary: FGF23, an endocrine growth factor, plays a pivotal role in phosphate homeostasis. Research has shown the presence of FGF23 and alpha Klotho protein in the hypothalamus, suggesting a potential role for FGF23 in the brain. However, gene expression of FGF23 was not detected in the brain, indicating that the observed FGF23 protein may not be brain-derived.
EUROPEAN JOURNAL OF NEUROSCIENCE
(2021)
Article
Cardiac & Cardiovascular Systems
Shejuti Paul, Mandy Wong, Ehimare Akhabue, Rupal C. Mehta, Holly Kramer, Tamara Isakova, Mercedes R. Carnethon, Myles Wolf, Orlando M. Gutierrez
Summary: In middle-aged adults with few comorbidities, higher levels of fibroblast growth factor 23 (FGF23) were not independently associated with greater risk of cardiovascular events or death. Higher cFGF23 was independently associated with greater risk of heart failure hospitalization.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Medicine, Research & Experimental
Tomohiro Saito, Masahide Mizobuchi, Tadashi Kato, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda
Summary: This study investigated the effect of continuous intravenous (CIV) FGF23 loading on cardiac function in a mouse model of mild chronic kidney disease and hypertension with heart failure. The results showed that CIV FGF23 loading exacerbated cardiac fibrosis, and abnormal vitamin D metabolism was involved in this mechanism. Calcitriol attenuated this exacerbation by mediating transforming growth factor-13 signaling independently of the FGF23 levels.
LABORATORY INVESTIGATION
(2023)
Article
Cardiac & Cardiovascular Systems
William Tucker, Bradley Tucker, Kerry-Anne Rye, Kwok Leung Ong
Summary: Fibroblast growth factor 21 (FGF21) is a hormone involved in energy regulation and has been shown to protect against obesity and diabetes. However, its role in heart failure (HF) is not well understood. HF is a global health problem with a rising prevalence, especially in aging populations. The emergence of cardiac biomarkers has been of great interest in improving prediction, diagnosis, and prognosis of HF. Recent studies suggest that FGF21 may be a promising biomarker for HF, but there are conflicting findings in clinical literature. Further research is needed to understand the causal role of FGF21 in HF and its potential as a biomarker for prediction, diagnosis, and prognosis.
HEART FAILURE REVIEWS
(2023)
Article
Cardiac & Cardiovascular Systems
Giuseppe Vergaro, Annamaria Del Franco, Alberto Aimo, Francesco Gentile, Vincenzo Castiglione, Federica Saponaro, Silvia Masotti, Concetta Prontera, Niccolo Fusari, Michele Emdin, Claudio Passino
Summary: Circulating iFGF23 is associated with the severity and outcome of HF in patients with reduced and mildly reduced ejection fraction.
BMC CARDIOVASCULAR DISORDERS
(2023)
Article
Medicine, General & Internal
Hyo Jin Kim, Yunmi Kim, Minjung Kang, Seonmi Kim, Sue Kyung Park, Suah Sung, Young Youl Hyun, Ji Yong Jung, Curie Ahn, Kook-Hwan Oh
Summary: This study evaluated the impact of the soluble Klotho and circulating FGF23 ratio on the risk of renal progression, cardiovascular events, and mortality in CKD. The results indicated that a low Klotho/FGF23 ratio was associated with an increased risk of renal events.
FRONTIERS IN MEDICINE
(2022)
Article
Urology & Nephrology
Christopher Yanucil, Dominik Kentrup, Isaac Campos, Brian Czaya, Kylie Heitman, David Westbrook, Gunars Osis, Alexander Grabner, Adam R. Wende, Julian Vallejo, Michael J. Wacker, Jose Alberto Navarro-Garcia, Gema Ruiz-Hurtado, Fuming Zhang, Yuefan Song, Robert J. Linhardt, Kenneth White, Michael S. Kapiloff, Christian Faul
Summary: Fibroblast growth factor (FGF) 23 is an elevated phosphate-regulating hormone in patients with chronic kidney disease and associated with cardiovascular mortality. This study found that soluble klotho and heparin regulate FGF23 signaling and effects in cardiac myocytes, with opposite effects.
KIDNEY INTERNATIONAL
(2022)
Article
Urology & Nephrology
Nattha Pramong, Pongsathorn Gojaseni, Sarunyoo Suttipongkeat, Kraiwiporn Kiattisunthorn, Anutra Chittinandana
Summary: This study found that elevated plasma c-FGF23 levels were associated with an increased risk of AKI in patients with ADHF, and plasma c-FGF23 shows potential in predicting AKI. These results should be validated in larger-scale studies to confirm their significance.
Article
Biochemistry & Molecular Biology
Anna Kurpas, Karolina Supel, Paulina Wieczorkiewicz, Joanna Bodalska Duleba, Marzenna Zielinska
Summary: This study examined the hypothesis that elevated FGF23 levels may be a CV risk factor among patients with long-standing type 2 diabetes mellitus. The study found that FGF23 was elevated in all patients, regardless of ischemic heart disease status, suggesting that its role as a CV risk factor may not be overestimated.
Article
Cardiac & Cardiovascular Systems
S. Heleen Binnenmars, Georgette E. Hoogslag, Stanley M. H. Yeung, Frank P. Brouwers, Stephan J. L. Bakker, Wiek H. van Gilst, Ron T. Gansevoort, Gerjan Navis, Adriaan A. Voors, Martin H. de Borst
Summary: This study found a significant association between higher FGF23 levels and new-onset HFrEF, but the association with HFpEF lost statistical significance after adjusting for potential confounders.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Urology & Nephrology
S. Madison Thomas, Qing Li, Christian Faul
Summary: This article discusses the physiological and pathological effects of fibroblast growth factor (FGF) 23, focusing on its receptors and co-receptors. Recent studies have shown that Klotho acts as a co-receptor for FGF23, and soluble klotho (sKL) and heparan sulfate (HS) have emerged as circulating co-receptors for FGFR that modulate the actions of FGF23. Experimental studies suggest that sKL protects against CKD-associated heart injury, while HS accelerates it. However, the relevance of these findings in vivo is still speculative.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
(2023)
Review
Medicine, General & Internal
Javier Donate-Correa, Ernesto Martin-Nunez, Ainhoa Gonzalez-Luis, Carla M. Ferri, Desiree Luis-Rodriguez, Victor G. Tagua, Carmen Mora-Fernandez, Juan E. Navarro-Gonzalez
Summary: Observational studies have linked the increase in FGF23 levels with the onset of diabetes, suggesting the existence of potential diabetogenic mechanisms originating from chronic supraphysiological levels of FGF23 in CKD and ESRD patients. These mechanisms could involve direct and indirect effects on pancreatic ss cells, as well as the stimulation of pro-inflammatory factors synthesis, potentially mediated by the binding of FGF23 to noncanonical receptor complexes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Marc P. Bonaca, Richard T. George, David A. Morrow, Brian A. Bergmark, Jeong-Gun Park, Liron Abuhatzira, Andrea L. Vavere, Sotirios K. Karathanasis, ChaoYu Jin, Dewei She, Boaz Hirshberg, Judy Hsia, Marc S. Sabatine
Summary: The study demonstrated that multiple ascending doses of MEDI6012 were safe and well tolerated, and significantly increased HDL-C, HDL cholesteryl ester, and total cholesteryl ester levels in a dose-related manner. These findings support the ongoing Phase 2b program investigating MEDI6012 in ST-elevation MI.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Article
Cardiac & Cardiovascular Systems
Evangelia Vemmou, Ilias Nikolakopoulos, Iosif Xenogiannis, Judit Karacsonyi, Bavana V. Rangan, Santiago Garcia, Martin Nicholas Burke, Hani Jneid, Kevin J. Croce, Brian A. Bergmark, Emmanouil S. Brilakis
Summary: The survey results showed that interventional cardiologists are highly likely to adopt innovation in daily clinical practice, with most willing to try new technologies and equipment. However, some still have doubts about using new equipment, mainly due to high costs and uncertain benefits compared to existing equipment.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Cardiac & Cardiovascular Systems
Brian A. Bergmark, Nicholas A. Marston, Candace R. Bramson, Madelyn Curto, Vesper Ramos, Alexandra Jevne, Julia F. Kuder, Jeong-Gun Park, Sabina A. Murphy, Subodh Verma, Wojtek Wojakowski, Steven G. Terra, Marc S. Sabatine, Stephen D. Wiviott
Summary: The study found that vupanorsen significantly reduced non-HDL-C and triglyceride levels, and had an impact on ANGPTL3 levels. However, higher doses may lead to injection site reactions and elevated liver enzymes.
Article
Cardiac & Cardiovascular Systems
Remo H. M. Furtado, Antonio Aurelio Fagundes, Kazuma Oyama, Thomas A. Zelniker, Minao Tang, Julia F. Kuder, Sabina A. Murphy, Andrew Hamer, Huei Wang, Anthony C. Keech, Robert P. Giugliano, Marc S. Sabatine, Brian A. Bergmark
Summary: The study found that evolocumab can reduce the risk of cardiovascular events in patients with prior PCI, including the risk of coronary revascularization, with consistent effects across different types of revascularization procedures.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Cardiac & Cardiovascular Systems
Jonathan G. Sung, Ajar Kochar, Kevin J. Croce, Brian A. Bergmark
Summary: True trifurcation disease in left main coronary artery is a rare but highly complex substrate for percutaneous coronary intervention. Evidence for optimal stenting strategy for such anatomy is lacking. We describe a novel three-stent strategy using a combination of double-kissing crush (DK crush) and Culotte techniques in three patients, and this approach appeared to be reproducible in all cases.
CARDIOVASCULAR REVASCULARIZATION MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Ajar Kochar, Brian A. Bergmark
Summary: Pulmonary embolism (PE) is a common, life-threatening and recurrent condition. The management of acute PE requires early detection, risk stratification and multidisciplinary decision-making. Catheter-directed interventions can help improve the condition of patients by increasing the cross-sectional area of the pulmonary vasculature, but integrating clinical trial evidence into individualized care remains a challenge.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Zaid Almarzooq, Brian A. Bergmark
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
David A. Morrow, Brian A. Bergmark
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
Brian A. Bergmark, Kai Ninomiya, Sabina A. Murphy, David van Klaveren, Peter K. Smith, Patrick T. Ogara, A. Pieter Kappetein, Seung-Jung Park, Dukwoo Park, Evald Christiansen, Niels R. Holm, Per Nielsen, Gregg Stone, Joseph F. Sabik, Marc S. Sabatine, Patrick W. Serruys
Meeting Abstract
Cardiac & Cardiovascular Systems
N. A. Marston, B. A. Bergmark, C. R. Bramson, M. Curto, V. Ramos, A. Jevne, J. F. Kuder, J. -G. Park, S. A. Murphy, S. Verma, W. Wojakowski, S. G. Terra, S. D. Wiviott, M. S. Sabatine
Review
Medicine, General & Internal
Brian A. Bergmark, Njambi Mathenge, Piera A. Merlini, Marilyn B. Lawrence-Wright, Robert P. Giugliano
Summary: Although progress has been made in diagnosing and treating acute coronary syndromes, cardiovascular disease remains a leading cause of death globally. High-sensitivity troponin assays have allowed for rapid diagnosis in suspected cases. Dual antiplatelet therapy and additional preventive measures are recommended. The diagnosis and management of acute coronary syndromes continue to evolve, especially in response to the COVID-19 pandemic.
Correction
Medicine, General & Internal
M. S. Sabatine, B. A. Bergmark, S. A. Murphy
Meeting Abstract
Cardiac & Cardiovascular Systems
Brian Bergmark, Eric Alan Osborn, Ziad Ali, Aakriti Gupta, Kranthi K. Kolli, Julie Prillinger, Nick E. West, James Hasegawa, Kevin J. Croce, Eric Alexander Secemsky
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Meeting Abstract
Cardiac & Cardiovascular Systems
Heidi Lumish, Brandi L. Vollmer, Brian Bergmark, Kevin J. Croce, Eric Alexander Secemsky, Eric Alan Osborn, Rahul P. Sharma, Celina M. Yong, Muredach P. Reilly, Raj R. Makkar, Harlan M. Krumholz, Ziad Ali, Aakriti Gupta
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Ilias Nikolakopoulos, Evangelia Vemmou, Judit Karacsonyi, Lorenzo Azzalini, Brian A. Bergmark, Yiannis S. Chatzizisis, Allison B. Hall, Jason Wollmuth, Kevin Croce, Hani Jneid, Bavana Rangan, M. Nicholas Burke, Emmanouil S. Brilakis
Summary: This study aimed to assess current procedural strategies and perceptions for percutaneous coronary intervention (PCI) involving bifurcations. The survey results showed that the DK crush technique was the most frequently used 2-stent strategy. For left main lesions, approximately 25% of cases underwent bailout stenting after provisional strategy. For non-left main lesions, the use of intravascular imaging and coronary physiology was lower than for left main lesions.
JOURNAL OF INVASIVE CARDIOLOGY
(2022)